Doug Cole joined Flagship Pioneering in 2001. He focuses on life science.
He holds an A.B. magna cum laude with high distinction in English from Dartmouth College, where he was a senior fellow and a member of Phi Beta Kappa, and an M.D. from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology at the Massachusetts General Hospital in Boston, MA.
Before joining Flagship, Doug was instructor in neurology at Harvard Medical School and assistant in neurology at the Massachusetts General Hospital; medical director at Cytotherapeutics, in Providence, RI; and program executive at Vertex Pharmaceuticals, Inc., in Cambridge, MA.
At Flagship, Doug has co-founded Ensemble Therapeutics, Permeon Biologics, Moderna Therapeutics, Syros Pharmaceuticals (NASDAQ:SYRS), Sigilon Therapeutics, and Foghorn Therapeutics. He has led investments in Agios Pharmaceuticals (NASDAQ:AGIO), Alvine Pharmaceuticals, Avedro, CombinatoRx (NASDAQ:ZLCS), Concert Pharmaceuticals (NASDAQ:CNCE), Denali Therapeutics, Editas (NASDAQ:EDIT), Quanterix Corporation, Receptos (NASDAQ:RCPT), Seventh Sense Biosystems, Tetraphase Pharmaceuticals (NASDAQ:TTPH), and Torque. He currently serves on the board of directors of Denali, Editas, Foghorn, Quanterix, Sigilon, Taris, and Torque. He formerly served on the board of directors of Avedro, AVEO Pharmaceuticals (NASDAQ: AVEO), CombinatoRx, Concert, CGI, KSQ, Moderna, Morphotek, Receptos, Resolvyx, Selecta (NASDAQ:SELB), Seventh Sense and Tetraphase.
Doug is a member of the scientific advisory board and the board of directors of the Spinal Muscular Atrophy Foundation.